positive: the sourced evidence makes a specific case that the business is improving or under-appreciated. medium conviction: a reasonable case, resting on fewer or partly second-hand sources.
- the case, in short
The international business grew 34.5% to INR1,665 crores and made up 59% of consolidated revenues, while India grew 12% to INR1,155 crores.
“India grew 12% to INR1,155 crores. And our international business grew 34.5% to INR1,665 crores, accounting for 59% of our consolidated revenues.”Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
- the main risk
Net debt stood at INR1,317 crores as of September, up INR263 crores from March '26.
“Net debt as of September stood at INR1,317 crores, an increase of INR263 crores over March '26.”Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
in plain words
The international business grew 34.5% to INR1,665 crores and made up 59% of consolidated revenues, while India grew 12% to INR1,155 crores. The company raised its full-year FY27 revenue growth outlook and now expects revenue growth to exceed 20%, compared with the mid-teens it gave earlier. Net debt stood at INR1,317 crores as of September, up INR263 crores from March '26.
why it may work
The international business grew 34.5% to INR1,665 crores and made up 59% of consolidated revenues, while India grew 12% to INR1,155 crores.
“India grew 12% to INR1,155 crores. And our international business grew 34.5% to INR1,665 crores, accounting for 59% of our consolidated revenues.”Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
The company raised its full-year FY27 revenue growth outlook and now expects revenue growth to exceed 20%, compared with the mid-teens it gave earlier.
“to raise our full year FY '27 revenue growth outlook. We now expect revenue growth to exceed 20% compared to mid-teens mentioned earlier.”Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
what could go wrong
Net debt stood at INR1,317 crores as of September, up INR263 crores from March '26.
“Net debt as of September stood at INR1,317 crores, an increase of INR263 crores over March '26.”Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Finance cost was INR36 crores, reflecting higher borrowings that were taken to fund acquisition-related payouts.
“Finance cost was INR36 crores, reflecting the increase in borrowings. The increased borrowings were to fund acquisition-related payouts.”Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Other income fell to INR16 crores from INR39 crores a year earlier, mainly because of lower foreign exchange gains.
“Other income was INR16 crores compared to INR39 crores last year, primarily on account of lower foreign exchange gains.”Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
price and valuation facts
- Closed 0.7% below its 52-week closing high.
- Last close ₹2,342.15 sits 98% of the way from the 52-week closing low (₹1,356.35) to the high (₹2,358.65).
- Its largest fall from a peak in the last year was 12.9% (maximum drawdown).
- P/E of 47.21x (standalone) is 28% below the median of its BSE 500 industry peers (sector peers when the industry has fewer than four).
- Annualised volatility over 3 months is 34.8%, higher than 67% of the BSE 500 scrips Dalal tracks.
- Median daily BSE traded value: ₹1.21 crore over 60 days.
dalal's own computed data (from exchange prices and bse fundamentals), not from the documents above. as of 16 nov 2026.
what is coming up
no dated events in the sources.
what would change the view
the view rests on these. if they stop being true, so does the view.
The company said it expects FY27 EBITDA margin improvement to be at the upper end of its 75 to 100 basis point guidance range.
“EBITDA margin improvement for the year is now expected to be at the upper end of our guidance range of 75 to 100 basis points.”Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
The company said it remains committed to becoming net cash by the end of FY28.
“We remain committed to our objective of becoming net cash by the end of FY '28.”Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
the numbers
computed by dalal when the note was written.
price
- last close
- ₹2,342.15
- 1-day change
- −0.70%
- 52-week high (closing basis)
- ₹2,358.65
- 52-week low (closing basis)
- ₹1,356.35
- 52-week high (BSE, adjusted)
- ₹2,394.55
- 52-week low (BSE, adjusted)
- ₹1,325.00
as of 16 nov 2026
returns
- 1-week return
- 5.69%
- 1-month return
- 28.47%
- 3-month return
- 24.93%
- 6-month return
- 38.98%
- 12-month return
- 70.70%
- 3-month return relative to SENSEX
- 18.27%
- 6-month return relative to SENSEX
- 27.48%
- 12-month return relative to SENSEX
- 75.81%
as of 16 nov 2026
risk
- annualised volatility (3 months)
- 34.78%
- maximum drawdown (1 year)
- −12.89%
- distance from 52-week closing high
- −0.70%
- 5-day vs 60-day BSE volume
- 5.00×
as of 16 nov 2026
valuation
- P/E (standalone)
- 47.21×
- P/E (consolidated)
- 40.66×
- P/B
- 15.71×
- EPS (standalone)
- ₹49.61
- EPS (consolidated)
- ₹57.60
- P/E relative to industry median
- 0.72×
as of 16 nov 2026
quality
- return on equity
- 33.27%
- operating margin
- 25.77%
- net margin
- 14.89%
as of 16 nov 2026
size & liquidity
- median daily BSE traded value (60 days)
- ₹1 cr
- market capitalisation
- ₹44,433 cr
as of 16 nov 2026
latest results (standalone)
- revenue, standalone (Sep-26)
- ₹1,668 cr
- net profit, standalone (Sep-26)
- ₹248 cr
- EPS, standalone (Sep-26)
- ₹13.10
- operating margin, standalone (Sep-26)
- 25.77%
- revenue, standalone (Jun-26)
- ₹1,451 cr
- net profit, standalone (Jun-26)
- ₹200 cr
- EPS, standalone (Jun-26)
- ₹10.55
- operating margin, standalone (Jun-26)
- 25.13%
- revenue change Jun-26 → Sep-26
- 14.96%
- net profit change Jun-26 → Sep-26
- 24.15%
as of 14 nov 2026
dalal scores
- daily score
- 100/100
- monthly score
- 96/100
- six-month score
- 99/100
- long-term score
- 83/100
as of 16 nov 2026
not available: next results board meeting; days since last results filing.
P/E: the share price divided by the profit per share over the last year · market cap: the total value of all of a company’s shares at the current share price · Sensex: the main index of BSE, tracking the share prices of a fixed group of large companies. fundamentals from bse are standalone figures. scores are percentile ranks across the bse 500 (90 = better than 90% of them on that horizon’s recipe). 7 statements passed dalal’s source checks. 2 did not and are not shown.
pick history
every time it was listed, and how it went.
never on a list so far.
in the knowledge base
the latest filings and news.
- Emcure Pharmaceuticals Promotes Amarendra Kumar to Executive Vice Presidentnewshrtoday.in· 15 nov 2026(opens the source in a new tab)
- Emcure Pharmaceuticals Ltd: Intimation Of Cancellation Of Schedule Of Analyst/ Investor Meeting(S) Scheduled On November 16, 2026filingbse· 14 nov 2026(opens the source in a new tab)
- Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcomefilingbse· 6 nov 2026(opens the source in a new tab)
- Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimationfilingbse· 6 nov 2026(opens the source in a new tab)
- Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Investor Presentationfilingbse· 6 nov 2026(opens the source in a new tab)
- Emcure Pharmaceuticals to attend JM Financial India conference on Nov 16newsscanx· 6 nov 2026(opens the source in a new tab)
- Emcure Pharmaceuticals Ltd: Announcement under Regulation 30 (LODR)-Newspaper Publicationfilingbse· 5 nov 2026(opens the source in a new tab)
- Emcure Pharmaceuticals posts 24% revenue growth in Q2 FY27; profit jumps 29%newsindian pharma post· 4 nov 2026(opens the source in a new tab)
- Emcure Pharmaceuticals Q2FY27 Results: Standalone PAT up 111% YoYnewsscanx· 4 nov 2026(opens the source in a new tab)
- Nifty 500: Emcure hits record high on strong Q2; MCX slips 5% despite doubling profit at market opennewscnbc-tv18· 4 nov 2026(opens the source in a new tab)
research ideas and things to consider, not personalised investment advice. every statement links to the filing or article it came from; numbers are computed by dalal from exchange data with their dates. ideas can and do lose money: the track record shows every pick, losers included. decide based on your own situation.